Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 3/2017

Open Access 01-06-2017 | State of the Art Review

Blood Biomarkers in Idiopathic Pulmonary Fibrosis

Authors: Julien Guiot, Catherine Moermans, Monique Henket, Jean-Louis Corhay, Renaud Louis

Published in: Lung | Issue 3/2017

Login to get access

Abstract

Purpose

Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disease of unknown origin whose incidence has been increasing over the latest decade partly as a consequence of population ageing. New anti-fibrotic therapy including pirfenidone and nintedanib have now proven efficacy in slowing down the disease. Nevertheless, diagnosis and follow-up of IPF remain challenging.

Methods

This review examines the recent literature on potentially useful blood molecular and cellular biomarkers in IPF. Most of the proposed biomarkers belong to chemokines (IL-8, CCL18), proteases (MMP-1 and MMP-7), and growth factors (IGBPs) families. Circulating T cells and fibrocytes have also gained recent interest in that respect. Up to now, though several interesting candidates are profiling there has not been a single biomarker, which proved to be specific of the disease and predictive of the evolution (decline of pulmonary function test values, risk of acute exacerbation or mortality).

Conclusion

Large scale multicentric studies are eagerly needed to confirm the utility of these biomarkers.
Literature
1.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824CrossRef
2.
Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174(7):810–816CrossRef
3.
King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083–2092CrossRef
4.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082CrossRef
5.
Maher TM (2013) PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 22(128):148–152CrossRef
6.
Kaarteenaho R, Lappi-Blanco E (2015) Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 8(1):3CrossRefPubMedPubMedCentral
7.
Zhang Y, Kaminski N (2012) Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 18(5):441–446CrossRef
8.
Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J et al (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192(2):e3–e19CrossRef
9.
10.
Morell F, Villar A, Montero M-Á, Muñoz X, Colby TV, Pipvath S et al (2013) Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 1(9):685–694CrossRef
11.
Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K et al (2002) Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165(3):378–381CrossRef
12.
Kobayashi J, Kitamura S (1995) KL-6: a serum marker for interstitial pneumonia. Chest 108(2):311–315CrossRef
13.
Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S et al (2010) Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med 104(8):1204–1210CrossRef
14.
Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K et al (2014) Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med 108(7):1031–1039CrossRef
15.
Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K et al (2008) Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer 122(11): 2612–2620CrossRef
16.
Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K (1997) KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol 17(4):501–507CrossRef
17.
Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N (2005) KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun 338(4): 1845–52CrossRef
18.
Satoh H, Kurishima K, Ishikawa H, Ohtsuka M (2006) Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 260(5):429–434CrossRef
19.
Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K et al (1998) Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158(5 Pt 1):1680–1684
20.
Guiot J, Bondue B, Henket M, Corhay JL, Louis R (2016) Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC Pulm Med 16(1):86CrossRefPubMedPubMedCentral
21.
Ishii H, Mukae H, Kadota J, Kaida H, Nagata T, Abe K et al (2003) High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax 58(1):52–57CrossRef
22.
Kohno N, Yokoyama A, Hirasawa Y, Kondo K, Fujino S, Abe M et al (1997) Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7 S in patients with interstitial pneumonitis and alveolar pneumonia. Respir Med 91(9):558–561CrossRef
23.
Greene KE, King TE, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS et al (2002) Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 19(3):439–446CrossRef
24.
Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI et al (2009) Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 135(6):1557–1563CrossRef
25.
Barlo NP, van Moorsel CHM, Ruven HJT, Zanen P, van den Bosch JMM, Grutters JC (2009) Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffus lung Dis 26(2):155–161
26.
Vázquez de Lara L, Becerril C, Montaño M, Ramos C, Maldonado V, Meléndez J et al (2000) Surfactant components modulate fibroblast apoptosis and type I collagen and collagenase-1 expression. Am J Physiol Lung Cell Mol Physiol 279(5):L950–L957
27.
Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y et al (2000) Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 162(3 Pt 1):1109–1114
28.
van Moorsel CHM, van Oosterhout MFM, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJT et al (2010) Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med 182(11):1419–1425
29.
Oikonomidi S, Kostikas K, Tsilioni I, Tanou K, Gourgoulianis KI, Kiropoulos TS (2009) Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr Med Chem 16(10):1214–1228CrossRefPubMed
30.
Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE et al (2008) MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 5(4):e93CrossRefPubMedPubMedCentral
31.
Vij R, Noth I (2012) Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 159(4):218–227CrossRef
32.
Dancer RCA, Wood AM, Thickett DR (2011) Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 38(6):1461–1467CrossRef
33.
Fujishima S, Shiomi T, Yamashita S, Yogo Y, Nakano Y, Inoue T et al (2010) Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arch Pathol Lab Med 134(8):1136–1142
34.
Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell A-M, Braybrooke R et al (2015) Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet. Respir Med 3(6):462–472CrossRef
35.
Chien J, Shao L, Lyman S, Adamkewicz J, Smith V, O’Riordan T (2014) Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF). Eur Respir J 40(Suppl 56)
36.
Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L et al(2014) Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 43(5):1430–1438CrossRef
37.
38.
Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K et al (2011) Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 37(5):1119–1127CrossRef
39.
Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA et al(2012) Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. AJP Lung Cell Mol Physiol 303(12):L1046–L1056CrossRef
40.
Hieshima K, Imai T, Baba M, Shoudai K, Ishizuka K, Nakagawa T et al (1997) A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol 159(3):1140–1149
41.
Prasse A, Pechkovsky D V, Toews GB, Jungraithmayr W, Kollert F, Goldmann T et al (2006) A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173(7):781–792CrossRef
42.
Prasse A, Pechkovsky DV, Toews GB, Schäfer M, Eggeling S, Ludwig C et al (2007) CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 56(5):1685–1693CrossRef
43.
Luzina IG, Tsymbalyuk N, Choi J, Hasday JD, Atamas SP (2006) CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 206(1):221–228CrossRef
44.
Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR et al (2009) Serum CC-Chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179(8):717–723CrossRef
45.
Saito Y, Azuma A, Matsuda K, Kamio K, Abe S, Gemma A (2016) Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation. Immunopharmacol Immunotoxicol 38(6):464–71CrossRef
46.
Tsoutsou PG, Gourgoulianis KI, Petinaki E, Germenis A, Tsoutsou AG, Mpaka M et al (2006) Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis. Respir Med 100(5):938–945CrossRef
47.
ZIEGENHAGEN MW, ZABEL P, ZISSEL G, SCHLAAK M, MÜLLER-QUERNHEIM J (1998) Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med 157(3):762–768CrossRef
48.
Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D et al (2012) Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 185(1):67–76CrossRef
49.
Ober C, Chupp GL (2009) The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immunol 9(5):401–408CrossRef
50.
Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret M-C et al (2008) YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 181(7):5167–5173CrossRefPubMed
51.
Korthagen NM, van Moorsel CHM, Barlo NP, Ruven HJT, Kruit A, Heron M et al (2011) Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med 105(1):106–113CrossRef
52.
Guiot J, Henket M, Corhay JL, Moermans C, Louis R (2017) Sputum biomarkers in IPF: Evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. PLoS ONE 12(2):e0171344.CrossRefPubMedPubMedCentral
53.
Shijubo N, Imai K, Aoki S, Hirasawa M, Sugawara H, Koba H et al (1992) Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis. Clin Exp Immunol 89(1):58–62
54.
Shijubo N, Imai K, Shigehara K, Hirasawa M, Tsujisaki M, Hinoda Y et al (1995) Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage (BAL) fluids of extrinsic allergic alveolitis. Clin Exp Immunol 102(1):91–97
55.
Monacci WT, Merrill MJ, Oldfield EH (1993) Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 264(4 Pt 1):C995–C1002
56.
Ando M, Miyazaki E, Ito T, Hiroshige S, Nureki S, Ueno T et al (2010) Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung 188(3):247–252.CrossRef
57.
Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S et al (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J
58.
Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ et al (2013) Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 187(7):768–775CrossRef
59.
Jaffar J, Unger S, Corte TJ, Keller M, Wolters PJ, Richeldi L et al (2014) Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. Chest 146(4):1055–1063CrossRef
60.
Cao M, Swigris JJ, Wang X, Cao M, Qiu Y, Huang M et al (2016) Plasma leptin is elevated in acute exacerbation of idiopathic pulmonary fibrosis. Mediators Inflamm 2016:1–7CrossRef
61.
White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR et al (2016) Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 194(10):1242–1251CrossRef
62.
Reilkoff RA, Peng H, Murray LA, Peng X, Russell T, Montgomery R et al (2013) Semaphorin 7a + regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1–induced pulmonary fibrosis. Am J Respir Crit Care Med 187(2):180–8CrossRef
63.
Gan Y, Reilkoff R, Peng X, Russell T, Chen Q, Mathai SK et al (2011) Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum 63(8):2484–2494CrossRef
64.
Kang H-R, Lee CG, Homer RJ, Elias JA (2007) Semaphorin 7 A plays a critical role in TGF-β 1 –induced pulmonary fibrosis. J Exp Med 204(5):1083–1093CrossRef
65.
Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N et al (2010) CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS ONE 5(1):e8959CrossRefPubMedPubMedCentral
66.
Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P et al (2009) Global impairment of CD4 + CD25 + FOXP3 + regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179(12):1121–1130CrossRef
67.
Vuga LJ, Tedrow JR, Pandit K V., Tan J, Kass DJ, Xue J et al (2014) C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 189(8):966–974CrossRef
68.
Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J et al (2009) Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179(7):588–594CrossRef
69.
Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY et al (2004) Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114(3):438–446CrossRef
70.
Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM (2007) Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 353(1):104–108CrossRef
71.
Daccord C, Maher TM (2016) Recent advances in understanding idiopathic pulmonary fibrosis. F1000Research 5
72.
Makiguchi T, Yamada M, Yoshioka Y, Sugiura H, Koarai A, Chiba S et al (2016) Serum extracellular vesicular miR-21-5p is a predictor of the prognosis in idiopathic pulmonary fibrosis. Respir Res 17(1):110CrossRefPubMedPubMedCentral
73.
Jiang X, Tsitsiou E, Herrick SE, Lindsay MA (2010) MicroRNAs and the regulation of fibrosis. FEBS J 277(9):2015–2021CrossRef
74.
Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M et al (2006) Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11(2):164–168CrossRef
75.
Ley B, Brown KK, Collard HR (2014) Molecular biomarkers in idiopathic pulmonary fibrosis. AJP Lung Cell Mol Physiol 307(9):L681–L691CrossRef
76.
Spagnolo P, Tzouvelekis A, Maher TM (2015) Personalized medicine in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 21(5):470–478
77.
DePianto DJ, Chandriani S, Abbas AR, Jia G, N’Diaye EN, Caplazi P et al (2015) Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 70(1):48–56CrossRef
78.
Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma S-F, Tseng GC et al (2013) Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 5(205):205ra136–205ra136CrossRef
Metadata
Title
Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Authors
Julien Guiot
Catherine Moermans
Monique Henket
Jean-Louis Corhay
Renaud Louis
Publication date
01-06-2017
Publisher
Springer US
Published in
Lung / Issue 3/2017
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-017-9993-5

Other articles of this Issue 3/2017

Lung 3/2017 Go to the issue

Airways Disease

Computed Tomography Findings of Bronchiectasis in Different Respiratory Phases Correlate with Pulmonary Function Test Data in Adults

Acute Lung Injury

Involvement of the Bufadienolides in the Detection and Therapy of the Acute Respiratory Distress Syndrome

Lung Cancer

Impact of Radiation Therapy in Surgically Resected Limited-Stage Small Cell Lung Carcinoma

COPD

Klotho Regulates Cigarette Smoke-Induced Autophagy: Implication in Pathogenesis of COPD

ACUTE LUNG INJURY

Chemokine Involvement in Lung Injury Secondary to Ischaemia/Reperfusion

LUNG IMAGES

Lung Image: Inflammatory Myofibroblastic Tumor
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits